OMER vs SHYF Comparison

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

The Shyft Group Inc is engaged in specialty vehicle manufacturing and assembly for commercial vehicles (including last-mile delivery, specialty service, and vocation-specific upfit segments) and recreational vehicle industries. Its products include walk-in vans, truck bodies, cargo vans, and pick-up truck upfits used in e-commerce/parcel delivery, upfit equipment used in the mobile retail and utility trades, as well as luxury Class A diesel motorhome custom chassis and contract manufacturing and assembly services. It also supplies replacement parts and offers repair, maintenance, field service, and refurbishment services for the vehicles that the company manufactures.